2025 Speakers

Esther Abels, founder & Chief Executive Officer, SolarisRTC LLC, co-founder & Chief Executive Officer, SolarisRTC Europe challenges the status quo to accelerate bringing innovative, emerging products to patients, globally by sharing her Regulatory, Clinical, Quality, In Vitro Diagnostics (IVD) and Pharma knowledge gained over the last 27 years.

She drives efforts for clarifying regulatory paths, reimbursement in Digital Pathology (DP) by collaborating with different Pathology Associations, Health Care Providers, Government and Payers. She successfully lead the reclassification of Whole Slide

Imaging Devices in Digital Pathology from a PMA (class III) to a 510(k) (class II), and successfully lead efforts to having Digital Pathology Artificial Intelligence (AI) algorithms certified under IVDRegulations in Europe, making the company she worked for at that time being the first achieving this in digital pathology.

In 2022 she was the president for the Digital Pathology Association, and has chaired its Regulatory and Standards Taskforce and Pharma TaskForce, the AIAct working group and co-founded the Pathology Innovation Collaborative Community. She currently is a member of the steering committee of the DDx foundation.

Angel Alberich-Bayarri is the Chief Executive Officer and co-founder of Quibim, a global company specializing in designing and developing pioneering tools that combine advanced medical image analysis and AI to achieve precise diagnoses and suitable treatments. Their recent solutions have focused on cancer detection and prediction. He holds a degree in Telecommunications Engineering from the Polytechnic University of Valencia and a doctorate in Biomedical Engineering. He is the inventor of 7 patents and has received numerous international awards for his innovative work, including the MIT Innovators Under 35. With 15 years of experience in the medical imaging and computer vision field, he possesses deep knowledge of the challenges and opportunities in diagnostics and drug development. He has authored over 100 articles in prestigious international journals and is a featured speaker at major international conferences.

Gabriele Allegri, M.B.A., serves as Vice President, Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine. In this capacity, Allegri develops and manages global commercial strategy as well as commercial collaborations with leading diagnostics companies to help ensure that its pharmaceutical products are directed to the right patients at the right time.

Suzzette Arnal is a leader in molecular oncology and precision medicine with over 20 years of experience expanding access and clinical adoption of innovative diagnostics. She combines scientific expertise and business acumen with a passion for operational excellence. Suzzette has held leadership roles at Quest Diagnostics and Castle Biosciences that spanned the full lifecycle of innovation – driving product development, validation, and commercialization. She earned her undergraduate degree in Biology from Columbia University and a Ph.D. in Molecular Oncology from New York University.

As Vice President of Precision Medicine, she leads initiatives that optimize laboratory services, reimagine the delivery of hereditary cancer genetics, and accelerate the adoption of precision medicine across The US Oncology Network, advancing enterprise-wide initiatives that incorporate biomarker testing, targeted therapies, and personalized care models for more than 600 community-based oncology sites of care and 2,500 oncology providers.

Mara Aspinall is a healthcare leader with a commitment to civic involvement. Aspinall is a Partner at Illumina Ventures, an independent, venture capital firm focused on genomics and precision health investing in diagnostics, life science tools and therapeutics.

Aspinall was President and CEO of Ventana Medical Systems, now Roche Tissue Diagnostics, a worldwide leader in tissue-based cancer diagnostics. Previously, Mara was President of Genzyme Genetics and Genzyme Pharmaceuticals.

Aspinall is passionate about diagnostics education. She publishes Sensitive & Specific: The Testing Newsletter and the annual Diagnostics Year in Review. This commitment to expanding knowledge inspired Aspinall to co-found the Biomedical Diagnostics Master Degree program at Arizona State University, the only program dedicated exclusively to diagnostics and testing.

During the pandemic, Aspinall emerged as a national authority on COVID testing. She was co-author of The Rockefeller Foundation’s reports on COVID policy.

Aspinall was Arizona Biosciences Leader of the Year by the Arizona BIO and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine.

Lourdes Barrera is Executive Director of Global Medical Affairs, Precision Medicine at Merck. She has held leadership roles at Novartis and AstraZeneca, where she built commercial and medical affairs capabilities and developed precision medicine strategies across multiple tumor types and hematological diseases.

Her early career spans over 15 years of experience as a clinical researcher in immunology, Lourdes initially focused on respiratory diseases and spent the last decade of this period specializing in lung cancer. She is also a professor of graduate and postgraduate courses, sharing her expertise with the next generation of scientists and clinicians.

Lourdes has authored more than 50 peer-reviewed publications and presented at numerous international congresses. She holds a Bachelor’s degree in Biology, Chemistry, and Pharmacy (honors), as well as dual doctorates in Immunology and Science Communication from the National Autonomous University of Mexico.

Dr. Tomasz (Tom) Beer serves as Vice President & Chief Medical Officer for Multi-Cancer Early Detection (MCED) at Exact Sciences Corporation. He oversees the clinical development of the company’s MCED test, to expand screening beyond the handful of cancers screened for today.

Prior to Exact Sciences, Dr. Beer was Chief Medical Officer and Deputy Cancer Center Director for the Center for Early Detection Advanced Research (CEDAR) where he led collaborations among clinicians, engineers, and cancer biologists and directed clinical trials of multi-omic blood-based cancer early detection tests.

Dr. Beer has authored or co-authored more than 290 peer reviewed articles on multi-cancer early detection, cancer survivorship, and emerging therapies. His work definitively showed overall survival gains with enzalutamide therapy, establishing a new standard of care for advanced prostate cancer.

Dr. Beer also maintains an adjunct faculty appointment at the Oregon Health & Science University (OHSU) Knight Cancer Institute, where he sees men with prostate cancer and serves on the American Cancer Society’s Discovery Council.

Suzanne Belinson, Ph.D., MPH, is Vice President of Commercial Markets at Tempus AI, Inc. Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI, in healthcare to create Intelligent Diagnostics.  Dr. Belinson’s role is focused on commercial growth through the development and execution of partnerships with managed care organizations. She is focused on improving healthcare value and outcomes by leveraging molecular and clinical data.

Previously, Dr. Belinson served as Executive Director, Clinical Markets, at the Blue Cross Blue Shield Association where she led the sales and market development as well as day to day operations of Evidence Street.

Dr. Belinson received her bachelor’s degree from Cleveland State University, a Masters in Public Health from the University of Pittsburgh, and a Ph.D. in Epidemiology from the University of North Carolina at Chapel Hill.

Cynthia A. Bens serves as the Senior Vice President for Public Policy at the Personalized Medicine Coalition (PMC). In this capacity, she leads the Coalition’s policy development and government relations efforts and serves as its primary liaison with the U.S. Congress and federal regulators. Bens is responsible for implementing research, regulatory, and reimbursement policy strategies that promote the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and health systems.

Doug Biehn is an accomplished leader with over 20 years of healthcare experience building and scaling growth businesses, leading and inspiring world class teams and establishing innovative new standards of care.

Prior to joining Octave, Doug held executive leadership roles in such category creating and industry leading companies as iRhythm Technologies, McKesson, AliveCor, Blue Shield of California and most recently, Cala Health. Additionally, he is a Board Advisor for a number of early-stage digital health companies and mentors graduate students in the Stanford Business School Lean Launchpad program.

Doug holds an MBA from the University of San Francisco and a BS from San Francisco State University.

Dynamic healthcare and academic leader with over 25 years of experience driving innovation in precision and preventive medicine, implementation science, translational and clinical research, and health system transformation. Passionate about shifting healthcare from reactive to proactive as well as health equity and wellness. Recognized for a strong track record of implementing precision medicine into clinical workflow with decision support, risk assessment tools to improve outcomes, and value-based care. Skilled in forging strategic partnerships across healthcare, academia, and industry. Led multi-million-dollar initiatives, established and scaled research centers, clinics, and precision health programs. Successfully secured tens of millions in competitive funding, with impactful publications and invited lectures across six continents aiming to advance personalized, proactive care.

Dr. Thomas Brown is an internationally renowned oncologist and cancer researcher, and the Chief Medical Officer of Sygnomics. He previously worked with the Swedish Cancer Institute (SCI) at Providence St. Joseph Health (PSJH), where he served as Executive Director of SCI, and led the establishment of the SCI Personalized Medicine Program. Dr. Brown also served in leadership roles across PSJH, including co-chair of the PSJH Cancer Leadership Council and co-chair of the PSJH Genomics Initiative.

Dr. Brown’s clinical and research efforts have been focused on gastrointestinal (GI) malignancies, broad developmental therapeutics in oncology, specifically phase I and II clinical trials, and health care policy and global medicine. He has been a leader in large-scale clinical trials and research programs for some of the most innovative academic medical centers and research collaborations and has spent the past decade pioneering approaches to real-world evidence in a health system setting.

Dr. Namandjé N. Bumpus serves as a strategic advisor in regulatory science and policy, formerly serving as the FDA’s Principal Deputy Commissioner until December 31, 2024. She began at the FDA in August 2022 as Chief Scientist before advancing to the agency’s no. 2 role, overseeing operations and public health initiatives. Prior to the FDA, Dr. Bumpus was the E.K. Marshall and Thomas H. Maren Professor and Director of Pharmacology and Molecular Sciences at Johns Hopkins University School of Medicine, following a postdoctoral fellowship at The Scripps Research Institute. She holds a PhD in pharmacology from the University of Michigan and a bachelor’s in biology from Occidental College. Dr. Bumpus is a past-president of the American Society for Pharmacology and Experimental Therapeutics, a fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine

Laura Carter, Ph.D. is the Chief Scientific Officer at Character Biosciences, a precision medicine company that is unlocking the patterns of progressive polygenic diseases in ophthalmology, starting with dry AMD. Following her PhD and postdoctoral studies in Molecular Pathology and Immunology, Dr. Carter has over 20 years of experience in the biotech/pharmaceutical industry where she has led R&D activities in multiple disease areas and contributed to the discovery and development of several approved drugs. Prior to joining Character Biosciences, Dr. Carter was the Chief Scientific Officer at Gossamer Bio where she was responsible for research, non-clinical development and translational biology across a diverse portfolio. Previously, Dr. Carter was Senior Vice President, Biology at Lycera Corporation, Scientific Director in the Respiratory, Inflammation and Autoimmunity group at MedImmune, and a Senior Research Investigator in the Inflammation Biology and Translational Science department at Array Biopharma. She started her industry career at Wyeth where her studies identified new cytokines and the negative regulatory role of PD-1:PD-L interactions on T cell function.

Dr. Castle has been responsible for the clinical development and performance of the Laboratory, Specialty Drug and Gene Therapy programs at EviCore by Evernorth for over 9 years. In addition to his 15 years of experience in the Specialty Drug field, Dr. Castle has been working in the genomic and molecular diagnostic field since 2007. During this time, he has been responsible for both designing initiatives that support the advancement of precision medicine and developing programs that ensure these tests are used appropriately.

Dr. Castle is board certified in Family Medicine. He completed his Sports Medicine fellowship at The Ohio State University in Columbus and practiced sports medicine for over a decade at the Baylor College of Medicine and the Baylor Sports Medicine Institute in Houston, Texas, serving as team physician for numerous professional, college, and high school sports teams.

Dr. Douglas P. Clark is a physician-scientist, pathologist, and health care executive whose career has spanned academic medicine, biomedical research, entrepreneurship, and health system executive leadership.   Doug is an expert in the fields of pathology artificial intelligence, cytopathology, and molecular diagnostics, and has authored over 80 peer-reviewed publications, several books and book chapters, is an inventor on several patents, and has given dozens of invited lectures nationally and internationally.

Dr. Clark currently serves as the Chief Pathologist for the Life Sciences and Diagnostics Markets Group at Agilent Technologies, a $6.51B company with customers in 110 countries. As Chief Pathologist, Doug is responsible for defining the vision and executing the Anatomic and Molecular Pathology strategy in this rapidly evolving field. Doug extensive expertise will play a critical role in implementing Agilent’s mission to improve the human condition by advancing precision medicine.

Stacy Cline Amin leads the global legal, regulatory affairs, and regulatory policy teams for Oracle’s Health and Life Sciences Legal & Compliance Group. She previously served as General Counsel of the Food and Drug Administration (FDA), leading an office of 170 lawyers and staff navigating complex legal, regulatory, litigation and compliance issues across the agency. She served as a Senior Associate Counsel in the White House in President Trump’s first term and also in the U.S. Senate and House of Representatives. After leaving the government, she chaired the global FDA & Healthcare Regulatory & Compliance practice at Morrison Foerster, advising pharma, biotech and medtech clients on their most complex challenges and strategic priorities. She began her career as a corporate lawyer at Sullivan & Cromwell and graduated from Harvard Law School.

Kristin Ciriello Pothier is the KPMG U.S. National Life Sciences Sector Leader, and the Global and National Healthcare and Life Sciences (HCLS) Deal Advisory & Strategy Leader. With almost 30 years in strategy consulting and scientific and clinical research; she focuses on commercial and growth strategy, and M&A for pharmaceutical, diagnostics, device, and consumer health companies, investors, and medical institutions worldwide. She is a leader in precision medicine and diagnostics innovations with hands-on experience developing product and service strategies across the Americas, Europe, Asia, and the Middle East. Her book, Personalizing Precision Medicine, has garnered attention worldwide for its all-inclusive and comprehensive look at global precision medicine.

Kristin also works with health systems and affiliated organizations on innovative services strategies, diligences, and operations, including clinical trial program development, laboratory builds, health IT, hospital services, and clinical outreach.

Earlier in her career, Kristin was a partner and the global head of Life Sciences Strategy at EY-Parthenon and a partner at Health Advances, where she built both from single-deal offices into global organizations. She started her career as a geneticist and clinical diagnostics developer at Genome Therapeutics and Genzyme/Sanofi.

Chris Dingman has over 24 years of experience in the healthcare industry. A top-performing, proven sales leader with extensive expertise in oncology molecular diagnostics and the pharmaceutical industries, Chris has a successful track record of developing and launching laboratory-developed tests by growing commercial and marketing capabilities. He has helped build top-tier, successful sales teams with a culture of putting patients and physicians first. Chris holds a BA in Marketing (cum laude) from the University of Colorado, Boulder, and an MBA in global management.

Okan Ekinci, M.D., M.B.A., is the Chief Medical Information Officer and Head of Digital Technology at Roche Information Solutions, Roche Diagnostics. He joined Roche in 2018 and served as Chief Medical Officer and Senior Vice President of Marketing & Innovation for the digital health business. Before that, Okan held various positions at Siemens Healthineers, including Chief Medical Officer and Head of Healthcare Consulting. He has been a strategic advisor to healthcare institutions and governments on digital transformation and artificial intelligence. Okan is a cardiologist by training and an adjunct professor of medicine at the University College Dublin.

Helmy Eltoukhy is the chairman and co-Chief Executive Officer of Guardant Health, a leading precision oncology company he co-founded in 2012. He is also an active investor and is involved in over 30 startup companies across the technology and healthcare sectors. Last year, Eltoukhy expanded his ventures into sports ownership by co-leading the acquisition of Sheffield United Football Club through COH Sports of which he is currently co-chairman.

This year, he was named by TIME100 Health as one of the most influential people in global health. He was also on Time Magazine’s inaugural list of the 50 Most Influential People in Health Care and has been recognized by Fortune (40 under 40), the World Economic Forum (Technology Pioneer), and on the list of the Top 50 Healthcare CEOs in 2021.

Beyond his entrepreneurial endeavors, Eltoukhy is deeply committed to various philanthropic efforts and serves on the boards of the Prostate Cancer Foundation, the SETI Institute (Search for Extraterrestrial Intelligence), and the UCSF Cancer Leadership Council. Prior to founding Guardant Health, Eltoukhy co-founded Avantome in 2007 to commercialize semiconductor sequencing, which was later acquired by Illumina. Eltoukhy is a named inventor on over 100 patents and holds PhD, MS, and BS degrees in electrical engineering from Stanford University.

Aradhana Ghosh, M.D. is a board-certified Medical Oncologist and seasoned Clinical Informaticist who currently serves as Vice President of Real-World Data Product Development at Labcorp. In this role, she leads a multi-disciplinary team of clinicians, scientists, and technologists who work cross-functionally as domain experts to build and implement data-centric products. For more than 10 years, Aradhana has been working at the intersection of clinical data and innovative technology to enable precision medicine and achieve better health outcomes.

Dr. Ghosh joined Labcorp in 2022, and prior to that, she held other positions including at Genentech/Roche, McKesson, and Kaiser Permanente where she began her clinical career. Aradhana earned her medical degree at Albany Medical College and completed residency and fellowship at Temple University Hospital and New York-Presbyterian/Weill Cornell Medical Center, respectively.

Dr. Gordon is the Clinical Director of Providence Health’s Population Genomics Program. In this role, Dr. Gordon leads system-wide clinical and research protocols for population genomic medicine across the Providence 50 hospital integrated network and is the principal investigator for the Geno4Me: Genomic Medicine for Everyone study and implementation studies of novel cell free DNA multicancer early detection blood tests for high-risk patients. Thousands of patients  have been enrolled in these prevention and early detection studies. Locally, she is Regional Medical Director of the Clinical Genetics & Genomics Program, Providence Southern California overseeing services throughout Los Angeles and Orange Counties.

Dr. Gordon is a professor of genetics at Saint John’s Cancer Institute (formerly John Wayne Cancer Institute) and professor of medicine at UCLA Geffen School of Medicine. In addition to her research publications, she also has co-authored an award-winning book for women facing genetic risk for breast or ovarian cancer, called Positive Results: Making the Best Decisions When at High Risk for Breast and Ovarian Cancer.

Brian Heath joined Kite in 2025 as Senior Vice President and Head of Global Commercial.

Brian is a highly accomplished leader with over 25 years of experience building and leading commercial teams across diverse geographies and therapeutic areas, with a strong focus in hematology and oncology. Prior to joining Kite, he served as Vice President and General Manager of Amgen’s US Oncology Business Unit, responsible for the commercialization of fifteen innovative and biosimilar medicines. His global experience includes leadership roles across Latin America, Turkey, the Middle East, Africa, and Canada, where he served as Vice-Chair of the Board of Innovative Medicines Canada.

He holds a bachelor’s degree from Brigham Young University and an MBA from the Harvard Business School. Brian is committed to community service, serving on the Board of Directors for Food Share of Ventura County.

Mr. Hickey is an attorney with O’Melveny & Myers, an international, 800-lawyer firm with 15 offices worldwide. He is a member of the Litigation Department and Director of the firm’s eDiscovery staff attorneys, leading operations firmwide. He served as an Infantry officer in the U.S.M.C. as a Lieutenant with postings in Quantico and Camp Pendleton.

His public service career includes roles on Capitol Hill, at the United States Department of Commerce and, after September 11, 2001, as Senior Advisor for Homeland Security for the Director of the Office of Personnel Management under President George W. Bush. At OPM, Mr. Hickey served as liaison to Veteran Service Organizations and coordinated with Congress and the White House on veterans’ legal rights during civil service reforms. He is a recipient of a Silver Helmet Award from AMVETS.

Mr. Hickey supports veterans through the Inner City Law Center of Los Angeles. He is also active in the Armed Forces Committee and Veterans Legal Service Project of the Los Angeles County Bar Association, assisting veterans, military personnel, and reservists with legal needs.

Yaik Ho has a robust background in oncology and competitive analysis, with experience as Head of Competitor Analysis for the Oncology Business Unit at AstraZeneca from September 2015 to July 2017, where leadership in competitive analysis was pivotal. Prior to this role, Yaik Ho served as Director of Oncology, managing strategy and operations within the oncology division. At Prescient Healthcare Group from May 2012 to August 2015, planning and executing competitive tracking programs for pharmaceutical clients were key responsibilities, with a focus on oncology and related fields. Additionally, Yaik Ho worked as a Research Associate at Imperial College London from November 2011 to April 2012, contributing to scientific research in a collaborative setting. Educational qualifications include a Doctor of Philosophy (PhD) and a Master of Science (MSc) from the University of Leicester.

Damon Hostin Leads the Global Market Access at Illumina.  Previously, he led the Precision Medicine Alliance of Catholic Health Initiatives and Dignity Health/ CommonSpirit Health, bringing advanced diagnostic and data solutions to over 150 hospitals. Prior, he was clinical lead for Complete Genomics, driving genomic analysis for rare disease. Earlier, he was General Manager of the Life Science segment of Strategic Diagnostics’ antibody and assay business, including IVDs, research tools and therapeutic mAb generation. Earlier, Hostin was Head of Life Science GenVis Labs, a genetic Dx company purchased by Pfizer in 2005. As a founding member of Actinium Pharmaceuticals, he managed alliances in developing targeted oncology radiotherapeutics. As Team Leader, Sequencing at Celera Genomics, he was published on the Human and Drosophila genomes in Science and contributed to pharmaceutical partnerships. His education includes undergraduate studies at Tulane University, Master’s studies at Harvard University, and certificate programs at TIGR, the NIH, and Wharton.

Steve works with exceptional scientists and entrepreneurs to help build companies that seek to create vast improvements in patient care and rewarding professional opportunities for employees.

Steve co-led investment and served as both founding Chief Executive Officer and Executive Chairman of Thrive Earlier Detection, a healthcare company advancing a breakthrough blood test for the earlier detection of multiple types of cancer. Thrive was acquired by Exact Sciences in January 2021. Steve also served as Executive Chairman at the molecular technology company ArcherDX, Inc., which was acquired by Invitae in October 2020. Steve also led Section 32’s investments in C2i Genomics, CelsiusTx, and Glympse Bio where he is also Chairman.

Earlier, Steve was President and Chief Operating Officer at Foundation Medicine, which was acquired by Roche in 2018, and also held leadership roles with several biotechnology companies.

Steve holds a PhD degree in political economy and government from Harvard University and a BA degree in economics and political science from Stanford University.

Jonathan Katchmore has over 20 years of experience in the diagnostic/BioPharma industry. He currently serves as the Associate Vice President of Commercial Diagnostic Strategy at Lilly where he leads strategy and execution of all external commercial initiatives in the precision medicine space.  His focus is on working with external partners to develop innovation solutions that address the clinical practice gaps that inhibit patients from benefiting from a personalized medicine approach.  Prior to joining Lilly, Jonathan spent 6 years at Foundation Medicine where he launched Next Generation Sequencing into the market.

Eric A. Klein, M.D. is Distinguished Scientist at GRAIL. Previously he served as the Andrew C. Novick Distinguished Professor and Chair of the Glickman Urological and Kidney Institute and Lerner College of Medicine of the Cleveland Clinic, where he was also a member of the Department of Cancer Biology of the Cleveland Clinic Lerner Research Institute, the Taussig Cancer Institute, and the Genitourinary Malignancies Program in the Case Comprehensive Cancer Center. Dr. Klein was a Fellow in the Distinguished Careers Institute at Stanford University in 2022 and joined GRAIL in 2023. His recent work has focused on the clinical development of multicancer early detection tests.

Clifton Leaf, an adjunct professor of journalism at Columbia University’s Graduate School of Journalism, served as the editor-in-chief of FORTUNE from 2017 to 2021. During his tenure, FORTUNE won more than 70 top journalism prizes, substantially expanded its website, newsletter, premium subscription, podcast, and virtual conference businesses, and launched two new start-up businesses in career development and education, respectively. Prior to that he was FORTUNE‘s deputy editor, overseeing the acclaimed print magazine. In earlier years, he was a guest editor for the New York Times op-ed page and held senior positions at the Wall Street Journal’s SmartMoney magazine and at FORTUNE.

Cate Lockhart, PharmD, Ph.D. is the Chief Science Officer of the Academy of Managed Care Pharmacy (AMCP) and the Executive Director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) where she is responsible for all AMCP research programs, including those within the BBCIC multi-stakeholder research collaboration. She is a proven leader in health economics and outcomes research (HEOR), observational research, and managed care pharmacy through experience in the biopharmaceutical sector, experience as a consultant, and her current role at the AMCP. Cate has three undergraduate degrees: Electrical Engineering, Visual Communications, and Theatre Arts. She also has three advanced degrees: PharmD, M.S. in HEOR, and a Ph.D. in Pharmaceutical Sciences. She has one U.S. Patent.

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. In 2012, he joined the Food and Drug Administration and served as Director of the Center for Biologics Evaluation and Research from 2016 to 2025. During that time, he was integrally involved in the response to several public health emergencies and was elected to the National Academy of Medicine in 2022. He has published extensively and is a member of multiple professional societies. He is currently working as an independent consultant.

Dr. Dawn Mattoon is the Chief Executive Officer at Mercy BioAnalytics. She brings nearly 20 years of experience in the biotechnology industry and has held leadership positions in R&D, Strategy, and General Management for a series of exceptional companies including Invitrogen, Life Technologies, Thermo Fisher, and Cell Signaling Technology. Prior to joining Mercy, Dr. Mattoon served as the Senior Vice President for Clinical Diagnostics at Quanterix, where she led the development and commercialization of the company’s first two FDA authorized diagnostic tests for COVID-19, and received Breakthrough Device designations from the FDA for diagnostic tests in Alzheimer’s Disease and Multiple Sclerosis. She has developed and commercialized products across a range of proteomic and genomic technologies and is thrilled by the opportunity to bring the highly innovative Mercy Halo diagnostic test portfolio to patients. Dr. Mattoon earned her Ph.D. in Genetics with a focus in signal transduction from Yale University, where she also completed her postdoctoral fellowship.

Dr. Rob Monroe is a physician scientist currently serving as Chief Medical Officer for Leica Biosystems and Chief Scientific Officer, Oncology for Danaher Diagnostics. Prior to Danaher, Dr. Monroe served as Chief Medical Officer of Bio-Techne; Chief Medical Officer at Advanced Cell Diagnostics; VP of Laboratory Operations at Veracyte; and Chief Medical Officer at BioImagine, one of the pioneering digital pathology companies. During his industry career, Rob also co-founded OncoMDx, a molecular diagnostics laboratory that later became part of Core Diagnostics where he served as Chief Medical Officer and led an international digital pathology service. Before joining industry, Rob practiced pathology in the Central Coast of California following a Medical Scientist Training Program Scholarship at Harvard Medical School and residency training at UCLA and Stanford.

Dr. Montalto is an industry leader in translational and precision medicine, digital pathology and AI for biomarker discovery.

Prior to Amgen, Dr. Montalto was the Chief Scientific Officer of PathAI, and Vice President of Translational Sciences at Bristol Myers Squibb. He has led teams to invent, develop and launch digital pathology, spatial multiplexing and AI-powered software applications as well as flagship biomarker testing programs such as PharmDx 28-8 (PD-L1/Agilent) for Opdivo, Yervoy and Opdualag.

Dr. Montalto serves on the Executive Committee of FNIH Biomarker Consortium, the editorial board of the Journal of AI in Precision Oncology and is a member of the Friends of Cancer Research Digital Pathology Working Group. He is the former President and board member of the Digital Pathology Association, has served as a scientific advisor to various multinational and start-up companies, holds 10 U.S. patents and has authored over 100 publications. Dr. Montalto earned his Ph.D. in tumor biology from Albany Medical College and completed post-doctoral training at Brigham and Women’s Hospital and Harvard Medical School.

David Morrow is the Scientific Lead for Advanced Therapies at EATRIS, where he drives the scientific strategy for Advanced Therapy Medicinal Products (ATMP) and Vaccines, Inflammation and Immune Monitoring (VIIM). He plays a central role in building European networks of scientific and clinical expertise to address shared challenges in translating ATMPs to the clinic and contributes to multiple EU-funded collaborative projects.David earned a BSc in Molecular Biology from University College Dublin (2001) and a Ph.D. in Vascular Biology from Dublin City University (2006), followed by an American Heart Association Fellowship at the University of Rochester, NY, where he received the AHA Young Investigator Award (2008). From 2009–2015, he was a Principal Investigator funded by the NIH and AHA, leading translational projects in cardiovascular disease and oncology. He also holds an MBA in Health Science Management and has worked in consulting and technology transfer. David serves on several Scientific Advisory Boards and international initiatives in the ATMP field.

Andy Moye is currently the Senior Vice President and General Manager of Real-World Data for Tempus AI, a company dedicated to improving patient outcomes through AI and data. He was previously Chief Executive Officer and board member for Paige, a spinout company from Memorial Sloan Kettering Cancer Center in New York City.  Andy has always been driven to serve others, and began his career as a Flight Officer in the US Navy, flying missions in Iraq and the Middle East from 1998 through 2006. Dr. Moye is also passionate about making a difference in the fight against cancer, and has worked across the molecular diagnostics, biotechnology, Real World Data (RWD), and life sciences industries at the forefront of precision medicine in oncology.  Notably, he served as Head of Commercial Operations in North America and Latin America for Philips Digital Pathology solutions, and in senior executive roles at leading healthcare companies including Ontada, a division of McKesson, Caris Life Sciences, and WaferGen Bio-systems, now part of Takara Bio. Andy Moye’s educational career includes a Bachelor of Science in Physiology from the University of Arizona, an M.B.A. from the University of Florida, and a Ph.D. in Health Economics from Walden University.

Susanne brings a wealth of experience to her role in leading a global team of precision medicine industry experts dedicated to enhancing the testing ecosystem to help patients capitalize on new breakthrough personalized medications. Susanne’s journey in molecular pathology has been marked by notable achievements, including spearheading several global launches of companion diagnostic products. As a leading author of the Practice Gaps Study, Susanne played a pivotal role in identifying 7 key clinical Practice Gaps contributing to patient leakage, and her impactful contributions to the field have earned her a well-deserved place among the PharmaVoice 100 list of transformational leaders in life sciences.

Brian Munroe is a founder of the Personalized Medicine Coalition. A 25-year veteran of health care public policy, advocacy, and communications, Brian’s areas of expertise include U.S. Food and Drug Administration-related legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine.

Lincoln Nadauld, M.D., Ph.D., is the Chief Executive Officer of Culmination Bio, a clinical insights company spun out of Intermountain Healthcare. Dr. Nadauld previously served as the Chief of Precision Health at Intermountain Healthcare, where he founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs. With this vision in mind, he oversaw the clinical implementation of precision genomics across Intermountain’s 24 hospitals and 160 physician clinics.

Dr. Omar Perez has over 17 years designing, deploying, and leading high-visibility oncology initiatives supporting global companion diagnostic developments, strategic partnerships and commercialization opportunities. Before joining AstraZeneca, he oversaw the global CDx developments for the GSK oncology portfolio, leading to diagnostic products for niraparib and dostarlimab. During his time at Pfizer, he led global CDx activities supporting the drug approvals of crizotinib, lorlatinib, dacomitinib talazoparib and inotuzomab. Notably, he led the first FDA approved NGS product for multiple targeted agents and helped establish the Center for Precision Medicine in LATAM to support Pfizer oncology products. Dr. Perez’s background includes roles in biotech and diagnostic companies, including co-founding Nodality, a diagnostic company focused on hematological malignancies. He is an inventor of the multiparametric phospho-proteomic flow technologies and an author of 37 publications and 35 patents.

Brad Perkins is the Chief Medical Officer at Karius, Inc., a global pioneer in clinical use of microbial cell-free DNA. He was founding Chief Medical Officer for Human Longevity, Inc. (HLI) where he designed the Health Nucleus, a leading precision medicine platform with genomics pioneer JC Venter.  Brad was EVP for Strategy and Innovation and Chief Transformation Officer at Vanguard Health Systems, an integrated health system in the run-up to its IPO, and subsequent sale to another publicly-traded healthcare company.  Brad started his career at the Centers for Disease Control and Prevention (CDC) where he led high profile investigations and research globally; he led the 2001 US anthrax bioterrorism investigations following 9/11. He served as the Chief Strategy and Innovation Officer at CDC. Brad has an M.D. and M.B.A., and is Board-certified in Internal Medicine.  He lives and works in San Diego and Redwood City, CA.

Kathryn founded the UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS) in 2008, a global leader in developing objective evidence on effectively, efficiently, and ethically implementing precision medicine. She has published over 200 articles in major journals (e.g., JAMA, NEJM, Science, Health Affairs); has led NIH grants for over 30 years; serves as the Founding Editor-in-Chief for Health Affairs Scholar; is a member of NAM committees (e.g., Roundtable on Genomics; Committee on Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden); and has served/is serving on an evidence review committee for the Institute for Clinical and Economic Review (ICER), GenomeCanada’s governing Board of Directors, and as an advisor to the FDA, CDC, AHRQ, President’s Council of Advisors on Science and Technology, and White House Office of Science and Technology Policy as well as many tech/pharma companies and venture capitalists. For several years, she has been among the top 2% of authors for career-long citations in her field (Ioannidis, 2024).

Prajit Pillai, Ph.D., is an accomplished scientist with extensive experience leading complex biotech and pharma projects from R&D through commercialization. He is the Co-Founder and Head of Business Strategy & Technology Development at Precision Medicine Diagnostic Partners, where he is developing AI-driven solutions to close cancer care gaps through custom clinical decision support tools. In addition, he serves as Director of Clinical Sciences at Cancer Commons, advancing their mission to leverage the latest research to improve patient outcomes. Passionate about harnessing technology to transform healthcare, Dr. Pillai actively partners with innovators to accelerate progress in cancer care.

Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist at Arizona State University’s Complex Adaptive Systems Initiative (CASI), which integrates genomics, synthetic biology, and high-performance computing to develop diagnostic technologies and remote health monitoring tools for precision medicine. He also leads the Institute for Future Health, a joint venture between ASU and the University of Arizona advancing digital and precision health.

From 2003 to 2009, Dr. Poste served as Founding Director of ASU’s Biodesign Institute. Earlier, he was Chief Science and Technology Officer and President of R&D at SmithKline Beecham (now GlaxoSmithKline), where he helped guide the development and approval of numerous drugs, vaccines, and diagnostic products.

Dr. Poste has published over 400 scientific papers, edited 14 books, and holds multiple honorary degrees. He has received major recognitions including the Commander of the British Empire, the Einstein Award, and the Scrip Lifetime Achievement Award.

He serves on the boards of Exelixis, Caris Life Sciences, and MediSix, and on the advisory boards of several research institutes and biotechnology companies. He is a Fellow of the Royal Society, the Royal College of Pathologists, the U.K. Academy of Medicine, and the American Institute for Medical and Biological Engineering.

Dr. Poste also advises U.S. defense, intelligence, and health agencies on biosecurity, emerging infectious diseases, and global biosurveillance.

Daryl Pritchard, Ph.D., is the Senior Vice President of Science Policy at the Personalized Medicine Coalition, where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory and payment policies.

Lauren Silvis serves as Senior Vice President of External Affairs at Tempus, overseeing regulatory, public policy, government affairs and strategic communications. She has held a number of senior career public health roles, serving as a Senior Advisor at the Department of Health and Human Services, Chief of Staff of the Food and Drug Administration and Deputy Center Director for Policy in FDA’s Center for Devices and Radiological Health. She currently serves as a member of the Council of Councils for the National Institutes of Health and Board Vice Chair for the Personalized Medicine Coalition. During her time in government, she advanced policies to promote innovation in precision medicine, real world evidence, clinical trials and digital health. Earlier in her career, she was a partner at the international law firm Sidley Austin LLP, focusing on regulation of pharmaceuticals and medical devices. Lauren graduated from Duke University and earned her law degree from Georgetown University Law Center.

Dr. Sireci is a board-certified Clinical Pathologist and a practicing molecular pathologist. Prior to joining Loxo, he was an Assistant Professor of Pathology and Cell Biology at Columbia University and a medical director in the Laboratory of Personalized Genomic Medicine at Columbia Medical Center. He is an active member of the Association for Molecular Pathology (AMP) where he serves on the organizations’ Strategy Committee and was the former vice chair for new codes and pricing on the Economic Affairs Committee. He is also a member of the Pathology Coding Caucus in the College of American Pathologists (CAP) and the Molecular Pathology Advisory Group in the American Medical Association (AMA). Dr. Sireci received a B.A. in chemistry from New York University, an M.D. from the Johns Hopkins University School of Medicine and a Masters in Biostatistics from the Mailman School of Public Health at Columbia University. He completed his residency training in Clinical Pathology in the New York-Presbyterian Hospital/Columbia, where he also served as chief resident.

Dr. Thomas Slavin is a physician-scientist and biotech executive, triple-board-certified in clinical genetics, molecular diagnostics and pediatrics. He is chief clinical officer of Molecular Oncology and Medical Director of Haystack Oncology at Quest Diagnostics. He previously held the positions of chief medical officer at Myriad Genetics and chief scientific officer at HALO Precision Diagnostics. He was a former assistant professor in the departments of Medical Oncology and Population Sciences at City of Hope National Medical Center.

Dr. Slavin graduated medical school with Alpha-Omega-Alpha-honors from the University of South Florida. He completed his residency programs at Case Western Reserve in Cleveland, Ohio where his training included a postdoctoral research year in genetic epidemiology. He has also completed graduate coursework toward a master’s degree in clinical research through the University of Southern California and holds a master’s in business administration through Columbia Southern University.

He is a clinical advisor for the breast screening awareness nonprofit Touch4Life. He is an active member of the American Association of Cancer Research, the American Society of Clinical Oncology (ASCO), the American Society of Human Genetics, the Collaborative Group of the Americas on Inherited Colorectal Cancer and is a fellow of the American College of Medical Genetics and Genomics. He has served on National Comprehensive Cancer Network (NCCN) committees for both the genetics of and screening for colorectal cancer. He has served on three ClinGen expert working group committees for variant classification of breast, gastrointestinal and ovarian cancer predisposition genes. Focused on expanding genetics education for cancer care providers, Dr. Slavin is an active faculty member of City of Hope’s hereditary genomics training program. He is a well-respected researcher in the field of medical genetics, publishing over 80 journal articles collectively evaluating genomic data from over 500,000 patients, multiple book chapters and providing numerous presentations at national and international medical meetings. He has been involved in many national cancer research grants and was a 2018 National Institutes of Health (NIH) K08-career development grant awardee.

AmirAli Talasaz is the co-Chief Executive Officer and co-founder of Guardant Health, a leading precision oncology company he co-founded in 2012 with Dr. Helmy Eltoukhy. Under AmirAli’s leadership, Guardant is transforming cancer care through advanced blood tests that discover cancer sooner and guide more precise treatment.

Talasaz has been recognized by TIME100 Health as one of the most influential people in global health, Fortune (40 under 40), was named to Time Magazine’s inaugural list of the 50 Most Influential People in Health Care, and as a recipient of the PMWC Luminary Award in 2024 for his work advancing the science of cancer care and screening.

Prior to co-founding Guardant Health in 2012, Talasaz founded Auriphex Biosciences, a transformative biotech focused on purification and genetic analysis of circulating tumor cells for cancer management, which was acquired by Illumina in 2009. At Illumina, he served as senior director of Diagnostics Research and led the efforts for emerging clinical applications of next-generation genomic analysis.

Dan Roden grew up in Montreal and received his medical degree at McGill University before fellowships in Clinical Pharmacology and Cardiology at Vanderbilt, where he joined the faculty.

His research examines how genetic variation affects human disease susceptibility, with special interests in pharmacogenetics and genetic determinants of abnormal heart rhythms, especially drug-induced.

After serving as chief of Clinical Pharmacology for 12 years, he began leading Vanderbilt’s Personalized Medicine program (2006), building internationally recognized initiatives including the >350K-sample biobank BioVU and the EHR-based preemptive pharmacogenetic program PREDICT. He served as PI for the Vanderbilt Pharmacogenomics Research Network (2001-2021), and now co-PI for the Electronic Medical Records and Genomics (eMERGE) Network (2007-2026), the genomic Learning Healthcare System (2024-2029), and the Data and Research Center for the US NIH All of Us program.

Dr. Roden has received numerous awards from the American Society for Clinical Pharmacology and Therapeutics, Heart Rhythm Society, American Heart Association, McGill, and  Ohio State University.  He has been elected to the American Society for Clinical Investigation, the Association of American Physicians, and fellowship in the American Association for the Advancement of Science.

Dr. Tsimberidou is a Professor of Medicine in the Department of Investigational Cancer Therapeutics, and a Katherine Russell Dixie Distinguished Endowed Professor at The University of Texas, MD Anderson Cancer Center. She has designed highly innovative clinical trials that have changed the standard of practice of oncology and improved the clinical outcomes of patients with solid tumors and hematologic malignancies. She pioneered the personalized medicine program across tumor types at M.D. Anderson. In 2007, she developed the IMPACT (Initiative for Personalized Medicine and Advanced Cancer Therapy) program and demonstrated that identifying tumor specific molecular aberrations and selecting therapy based on tumor abnormalities of individual patients with advanced cancer is associated with better overall outcomes compared with standard approaches. Her research accomplishments have garnered extensive media coverage by ASCO, The Economist, the Wall Street Journal, the Bloomberg report and the Boston Globe. She has published over 350 articles in high-impact peer-reviewed journals and book chapters and co-edited major textbooks in Oncology. She has been invited to present her work at numerous conferences. She has received prestigious awards, and she was appointed to serve on several committees at ASCO and the Worldwide Innovative Network (WIN) consortium in Precision Medicine. She is a board member of the Coalition for Personalized Medicine. Dr Tsimberidou is a Fellow of ASCO (FASCO) and a Fellow of the American Association for the Advancement of Science (AAAS) for “seminal contributions to instantiating and implementing precision oncology through innovative therapeutic approaches, patient care, and education aimed at improving clinical outcomes across tumor types”.

Alex Vadas, Ph.D. is a Managing Director and Partner in L.E.K. Consulting’s Healthcare practice and co-leads the Life Sciences Enablers practice.

He has worked with a broad range of financial and strategic clients from venture-backed to global multi-nationals in the areas of corporate strategy, product strategy and planning, and transaction support.

Alex focuses on major innovation areas in life sciences, including life sciences tools and technologies such as genomics, proteomics, cell analysis, multi-omics, and AI-enabled platforms. His work also spans diagnostics and precision medicine, with emphasis on advanced diagnostics, precision oncology, molecular diagnostics, liquid biopsy, and pathology. In addition, Alex is engaged in advanced therapy bioprocessing and manufacturing, covering monoclonal antibodies as well as cell, gene, and nucleic acid therapies.

He joined L.E.K. in 2000 and received both his Bachelor of Science and Doctorate of Philosophy degrees in chemical engineering from the University of California, Los Angeles.

Ayah Ziyada is the Precision Medicine Program Manager at the Center for Clinical Precision Medicine and Genomics, Hamad Medical Corporation (HMC) in Qatar, where she leads initiatives to position HMC as a model for precision medicine. She holds a BPharm from Dubai Medical University and a M.S. in Genomics and Precision Medicine from Hamad Bin Khalifa University, where her research explored innovative imputation strategies for underrepresented, low-coverage whole genomes.

Certified by the American Society of Health-System Pharmacists, Ayah is a member of the PGRN Global Committee, the CPIC Guideline Consortium, and the Consortium for Healthcare AI. Her expertise spans pharmacogenomics, AI-enabled healthcare, and deploying precision medicine innovations into clinical practice.

Ayah helped launch HMC’s first precision medicine incubation program, creating pathways for healthcare startups, business ventures, and industry partnerships to accelerate the adoption of validated technologies. She leads enterprise-wide projects that integrate precision medicine into clinical workflows, improve patient outcomes, and foster a culture of innovation.